Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis

Oncotarget

Volumn 6, Issue 9, 2015, Pages 7209-7220

  Mitsuhashi, Kei ^a   Nosho, Katsuhiko ^a   Sukawa, Yasutaka ^b   Matsunaga, Yasutaka ^a   Ito, Miki ^a   Kurihara, Hiroyoshi ^a   Kanno, Shinichi ^a   Igarashi, Hisayoshi ^a   Naito, Takafumi ^a   Adachi, Yasushi ^a   Tachibana, Mami ^a   Tanuma, Tokuma ^a,c   Maguchi, Hiroyuki ^c   Shinohara, Toshiya ^c   Hasegawa, Tadashi ^a   Imamura, Masafumi ^a   Kimura, Yasutoshi ^a   Hirata, Koichi ^a   Maruyama, Reo ^a   Suzuki, Hiromu ^a   Imai, Kohzoh ^d   Yamamoto, Hiroyuki ^e   Shinomura, Yasuhisa ^e   more..

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c TEINE KEIJINKAI HOSPITAL   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Fusobacterium; Microbiota; MiR 31; Pancreas; Survival

Indexed keywords

B RAF KINASE; MICRORNA 21; MICRORNA 31; TUMOR MARKER;

AGED; ARTICLE; BACTERIUM DETECTION; BRAF GENE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; CLINICAL FEATURE; CONTROLLED STUDY; CPG ISLAND; CPG ISLAND METHYLATOR PHENOTYPE; EPIGENETICS; FEMALE; FUSOBACTERIUM; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; ONCOGENE K RAS; ONCOGENE N RAS; PANCREAS ADENOCARCINOMA; PHENOTYPE; PIK3CA GENE; TUMOR GENE; COMPLICATION; DNA METHYLATION; DNA SEQUENCE; FUSOBACTERIUM INFECTION; GENE EXPRESSION PROFILING; GENETIC EPIGENESIS; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MICROBIOLOGY; MICROSATELLITE INSTABILITY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PANCREAS TUMOR; PATHOGENICITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REGRESSION ANALYSIS; TREATMENT OUTCOME;

AGED; BIOMARKERS, TUMOR; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; FUSOBACTERIUM; FUSOBACTERIUM INFECTIONS; GENE EXPRESSION PROFILING; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PANCREATIC NEOPLASMS; PHENOTYPE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME;

EID: 84927138939     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3109     Document Type: Article

References (50)

1. Vincent A, Hong SM, Hu C, Omura N, Young A, Kim H, Yu J, Knight S, Ayars M, Griffith M, Van Seuningen I, Maitra A, Goggins M. Epigenetic silencing of EYA2 in pancreatic adenocarcinomas promotes tumor growth. Oncotarget. 2014; 5:2575-2587.
2. Ma MZ, Kong X, Weng MZ, Cheng K, Gong W, Quan ZW, Peng CH. Candidate microRNA biomarkers of pancreatic ductal adenocarcinoma: meta-analysis, experimental vali-dation and clinical significance. J Exp Clin Cancer Res. 2013; 32:71.
3. Farrell JJ, Zhang L, Zhou H, Chia D, Elashoff D, Akin D, Paster BJ, Joshipura K, Wong DT. Variations of oral micro-biota are associated with pancreatic diseases including pan-creatic cancer. Gut. 2012; 61:582-588.
4. Risch HA. Pancreatic cancer: Helicobacter pylori coloniza-tion, N-nitrosamine exposures, and ABO blood group. Mol Carcinog. 2012; 51:109-118.
5. Mace TA, Collins AL, Wojcik SE, Croce CM, Lesinski GB, Bloomston M. Hypoxia induces the overexpression of microRNA-21 in pancreatic cancer cells. J Surg Res. 2013; 184:855-860.
6. Michaud DS. Role of bacterial infections in pancreatic can-cer. Carcinogenesis. 2013; 34:2193-2197.
7. Michaud DS, Izard J, Wilhelm-Benartzi CS, You DH, Grote VA, Tjonneland A, Dahm CC, Overvad K, Jenab M, Fedirko V, Boutron-Ruault MC, Clavel-Chapelon F, Racine A, Kaaks R, Boeing H, Foerster J, et al. Plasma antibodies to oral bacteria and risk of pancreatic cancer in a large European prospective cohort study. Gut. 2013; 62:1764-1770.
8. Wang P, Zhuang L, Zhang J, Fan J, Luo J, Chen H, Wang K, Liu L, Chen Z, Meng Z. The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR-21 expression confers chemo-resistance by targeting FasL. Mol Oncol. 2013; 7:334-345.
9. Frampton AE, Giovannetti E, Jamieson NB, Krell J, Gall TM, Stebbing J, Jiao LR, Castellano L. A microRNA meta-signature for pancreatic ductal adenocarcinoma. Expert Rev Mol Diagn. 2014; 14:267-271.
10. Michaud DS, Joshipura K, Giovannucci E, Fuchs CS.A prospective study of periodontal disease and pancreatic cancer in US male health professionals. J Natl Cancer Inst. 2007; 99:171-175.
11. Papaconstantinou IG, Manta A, Gazouli M, Lyberopoulou A, Lykoudis PM, Polymeneas G, Voros D. Expression of microRNAs in patients with pancreatic cancer and its prog-nostic significance. Pancreas. 2013; 42:67-71.
12. Ueki T, Toyota M, Sohn T, Yeo CJ, Issa JP, Hruban RH, Goggins M. Hypermethylation of multiple genes in pancre-atic adenocarcinoma. Cancer Res. 2000; 60:1835-1839.
13. Khan S, Ebeling MC, Zaman MS, Sikander M, Yallapu MM, Chauhan N, Yacoubian AM, Behrman SW, Zafar N, Kumar D, Thompson PA, Jaggi M, Chauhan SC. MicroRNA-14 tar-gets MUC13 and suppresses growth and invasion of pancre-atic cancer. Oncotarget. 2014; 5:7599-7609.
14. Ahn J, Segers S, Hayes RB. Periodontal disease, Porphyromonas gingivalis serum antibody levels and orodigestive cancer mortality. Carcinogenesis. 2012; 33:1055-1058.
15. Hayashi C, Gudino CV, Gibson FC, 3rd CA. Review: Pathogen-induced inflammation at sites distant from oral infection: bacterial persistence and induction of cell-specific innate immune inflammatory pathways. Mol Oral Microbiol. 2010; 25:305-316.
16. Swidsinski A, Dorffel Y, Loening-Baucke V, Theissig F, Ruckert JC, Ismail M, Rau WA, Gaschler D, Weizenegger M, Kuhn S, Schilling J, Dorffel WV. Acute appendicitis is characterised by local invasion with Fusobacterium nuclea-tum/necrophorum. Gut. 2011; 60:34-40.
17. Ohkusa T, Okayasu I, Ogihara T, Morita K, Ogawa M, Sato N. Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis. Gut. 2003; 52:79-83.
18. Minami M, Ando T, Okamoto A, Sasaki N, Ohkura T, Torii K, Hasegawa T, Ohta M, Goto H. Seroprevalence of Fusobacterium varium in ulcerative colitis patients in Japan. FEMS Immunol Med Microbiol. 2009; 56:67-72.
19. Strauss J, Kaplan GG, Beck PL, Rioux K, Panaccione R, Devinney R, Lynch T, Allen-Vercoe E. Invasive potential of gut mucosa-derived Fusobacterium nucleatum positively correlates with IBD status of the host. Inflamm Bowel Dis. 2011; 17:1971-1978.
20. Yoneda M, Kato S, Mawatari H, Kirikoshi H, Imajo K, Fujita K, Endo H, Takahashi H, Inamori M, Kobayashi N, Kubota K, Saito S, Tohnai I, Watanuki K, Wada K, Maeda S, et al. Liver abscess caused by periodontal bacterial infec-tion with Fusobacterium necrophorum. Hepatol Res. 2011; 41:194-196.
21. Athavale NV, Leitch DG, Cowling P. Liver abscesses due to Fusobacterium spp that mimick malignant meta-static liver disease. Eur J Clin Microbiol Infect Dis. 2002; 21:884-886.
22. Brook I, Frazier EH. Microbiological analysis of pancreatic abscess. Clin Infect Dis. 1996; 22:384-385.
23. Han XY, Weinberg JS, Prabhu SS, Hassenbusch SJ, Fuller GN, Tarrand JJ, Kontoyiannis DP. Fusobacterial brain abscess: a review of five cases and an analysis of possible pathogenesis. Journal of neurosurgery. 2003; 99:693-700.
24. Signat B, Roques C, Poulet P, Duffaut D. Fusobacterium nucleatum in periodontal health and disease. Curr Issues Mol Biol. 2011; 13:25-36.
25. Shahani L, Khardori N. Fusobacterium necrophorum-beyond Lemierres syndrome. BMJ case reports. 2011; doi:10.1136/bcr.07.2011.4527.
26. Kostic AD, Gevers D, Pedamallu CS, Michaud M, Duke F, Earl AM, Ojesina AI, Jung J, Bass AJ, Tabernero J, Baselga J, Liu C, Shivdasani RA, Ogino S, Birren BW, Huttenhower C, et al. Genomic analysis identifies associa-tion of Fusobacterium with colorectal carcinoma. Genome Res. 2012; 22:292-298.
27. Castellarin M, Warren RL, Freeman JD, Dreolini L, Krzywinski M, Strauss J, Barnes R, Watson P, Allen-Vercoe E, Moore RA, Holt RA. Fusobacterium nuclea-tum infection is prevalent in human colorectal carcinoma. Genome Res. 2012; 22:299-306.
28. Tahara T, Yamamoto E, Suzuki H, Maruyama R, Chung W, Garriga J, Jelinek J, Yamano HO, Sugai T, An B, Shureiqi I, Toyota M, Kondo Y, Estecio MR, Issa JP. Fusobacterium in colonic flora and molecular features of colorectal carci-noma. Cancer Res. 2014; 74:1311-1318.
29. Flanagan L, Schmid J, Ebert M, Soucek P, Kunicka T, Liska V, Bruha J, Neary P, Dezeeuw N, Tommasino M, Jenab M, Prehn JH, Hughes DJ. Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome. Eur J Clin Microbiol Infect Dis. 2014; 33:1381-90.
30. Kostic AD, Chun E, Robertson L, Glickman JN, Gallini CA, Michaud M, Clancy TE, Chung DC, Lochhead P, Hold GL, El-Omar EM, Brenner D, Fuchs CS, Meyerson M, Garrett WS. Fusobacterium nucleatum potentiates intestinal tumor-igenesis and modulates the tumor-immune microenviron-ment. Cell host & microbe. 2013; 14:207-215.
31. Fritz S, Hackert T, Hartwig W, Rossmanith F, Strobel O, Schneider L, Will-Schweiger K, Kommerell M, Buchler MW, Werner J. Bacterial translocation and infected pancreatic necrosis in acute necrotizing pancreatitis derives from small bowel rather than from colon. Am J Surg. 2010; 200:111-117.
32. Zheng L, Giri B. Gastrointestinal Variant of Lemierre Syndrome: Fusobacterium nucleatum Bacteremia-Associated Hepatic Vein Thrombosis: a Case Report and Literature Review. Am J Ther. (in press)
33. Pei Z, Bini EJ, Yang L, Zhou M, Francois F, Blaser MJ. Bacterial biota in the human distal esophagus. Proc Natl Acad Sci U S A. 2004; 101:4250-4255.
34. Aviles-Jimenez F, Vazquez-Jimenez F, Medrano-Guzman R, Mantilla A, Torres J. Stomach microbiota composition var-ies between patients with non-atrophic gastritis and patients with intestinal type of gastric cancer. Scientific reports. 2014; 4:4202.
35. Runkel NS, Rodriguez LF, Moody FG. Mechanisms of sepsis in acute pancreatitis in opossums. Am J Surg. 1995; 169:227-232.
36. Schetter AJ, Heegaard NH, Harris CC. Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis. 2010; 31:37-49.
37. Hughes LA, Melotte V, de Schrijver J, de Maat M, Smit VT, Bovee JV, French PJ, van den Brandt PA, Schouten LJ, de Meyer T, van Criekinge W, Ahuja N, Herman JG, Weijenberg MP, van Engeland M. The CpG island methylator phenotype: what's in a name? Cancer Res. 2013; 73:5858-5868.
38. Irahara N, Baba Y, Nosho K, Shima K, Yan L, Dias-Santagata D, Iafrate AJ, Fuchs CS, Haigis KM, Ogino S. NRAS mutations are rare in colorectal cancer. Diagn Mol Pathol. 2010; 19:157-163.
39. Ito M, Mitsuhashi K, Igarashi H, Nosho K, Naito T, Yoshii S, Takahashi H, Fujita M, Sukawa Y, Yamamoto E, Takahashi T, Adachi Y, Nojima M, Sasaki Y, Tokino T, Baba Y, et al. MicroRNA-31 expression in relation to BRAF mutation, CpG island methylation and colorec-tal continuum in serrated lesions. Int J Cancer. 2014; 135:2507-2515.
40. Dong J, Zhao YP, Zhou L, Zhang TP, Chen G. Bcl-2 upreg-ulation induced by miR-21 via a direct interaction is associ-ated with apoptosis and chemoresistance in MIA PaCa-2 pancreatic cancer cells. Arch Med Res. 2011; 42:8-14.
41. Nagao Y, Hisaoka M, Matsuyama A, Kanemitsu S, Hamada T, Fukuyama T, Nakano R, Uchiyama A, Kawamoto M, Yamaguchi K, Hashimoto H. Association of microRNA-21 expression with its targets, PDCD4 and TIMP3, in pancre-atic ductal adenocarcinoma. Mod Pathol. 2012; 25:112-121.
42. Farrell JJ, Toste P, Wu N, Li L, Wong J, Malkhassian D, Tran LM, Wu X, Li X, Dawson D, Wu H, Donahue TR. Endoscopically Acquired Pancreatic Cyst Fluid MicroRNA 21 and 221 Are Associated With Invasive Cancer. Am J Gastroenterol. 2013; 108:1352-1359.
43. Virtue A, Wang H, Yang XF. MicroRNAs and toll-like receptor/interleukin-1 receptor signaling. J Hematol Oncol. 2012; 5:66.
44. Honda T, Takahashi N, Miyauchi S, Yamazaki K. Porphyromonas gingivalis lipopolysaccharide induces miR-146awithout altering the production of inflammatory cytokines. Biochem Biophys Res Commun. 2012; 420:918-925.
45. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nature cell biology. 2007; 9:654-659.
46. Rechavi O, Erlich Y, Amram H, Flomenblit L, Karginov FV, Goldstein I, Hannon GJ, Kloog Y. Cell contact-dependent acquisition of cellular and viral nonau-tonomously encoded small RNAs. Genes & development. 2009; 23:1971-1979.
47. Tavano F, di Mola FF, Piepoli A, Panza A, Copetti M, Burbaci FP, Latiano T, Pellegrini F, Maiello E, Andriulli A, di Sebastiano P. Changes in miR-143 and miR-21 expres-sion and clinicopathological correlations in pancreatic can-cers. Pancreas. 2012; 41:1280-1284.
48. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005; 97:1180-1184.
49. Boutaga K, Winkelhoff AJ, Vandenbroucke-Grauls CM, Savelkoul PH. Periodontal pathogens: A quantitative com-parison of anaerobic culture and real-time PCR. FEMS Immunology & Medical Microbiology. 2005; 45:191-199.
50. Nosho K, Igarashi H, Nojima M, Ito M, Maruyama R, Yoshii S, Naito T, Sukawa Y, Mikami M, Sumioka W, Yamamoto E, Kurokawa S, Adachi Y, Takahashi H, Okuda H, Kusumi T, et al. Association of microRNA-31 with BRAF mutation, colorectal cancer survival and ser-rated pathway. Carcinogenesis. 2014; 35:776-783.